Back to search results

Study of VERVE-102 for High Cholesterol or Early Heart Disease

This study is testing VERVE-102, a new treatment for people with very high cholesterol due to Heterozygous Familial Hypercholesterolemia (HeFH) or those with Premature Coronary Artery Disease (CAD), which is heart disease that develops early in life. VERVE-102 is given through an IV (intravenous) infusion and uses a special technology to lower "bad" cholesterol (LDL-C) by targeting a specific gene in the liver. The main goal of this study is to see how safe VERVE-102 is and what side effects it might cause over about a year. You could be eligible if you are between 18 and 70 years old and have been diagnosed with HeFH or premature CAD. The study is currently recruiting about 85 participants.

Study design
This is an open-label, Phase 1b study, meaning both you and the study team will know you are receiving VERVE-102. It will involve a single dose of the treatment and aims to enroll 85 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Your safety will be monitored for up to 365 days after receiving the treatment.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06164730

A Study of VERVE-102 in Patients With Familial Hypercholesterolemia or Premature Coronary Artery Disease

Recruiting
PHASE1Ages 18–70InterventionalTreatment
Verve Therapeutics, Inc.
~85 participants
Updated 2026-08-03 on ClinicalTrials.gov
What's tested:VERVE-102

At a glance

Recruiting sites
27 of 27 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)
Measured over up to Day 365

Conditions

Heterozygous Familial Hypercholesterolemia
Premature Coronary Heart Disease

Explore related trials

Coronary Artery DiseaseFamilial hypercholesterolemia - heterozygous

Where it's being run

27 sites across 13 states
Canada6
United Kingdom6
Florida3
Australia3
Alabama1
California1
Indiana1
North Carolina1

Study leadership

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) · STUDY_DIRECTOR · Eli Lilly and Company

Who to contact

Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
[email protected]
317-615-4559
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Diagnosis of HeFH or premature CAD

Exclusion

Homozygous familial hypercholesterolemia
Active or history of chronic liver disease
Current treatment with PCSK9 inhibitor or prior treatment within specified timeframe
Clinically significant or abnormal laboratory values as defined by the protocol

What this trial measures

  • Incidence of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs)up to Day 365